Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
nab-paclitaxel + cisplatin
DRUG
2 trials
Sponsors
Huazhong University of Science and Technology
, Shanghai Chest Hospital
Conditions
Biliary Tract Cancer
Esophageal Squamous Cell Carcinoma
Unresectable Locally Advanced Esophageal Cancer
Phase 1
Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer
Recruiting
NCT06173986
Shanghai Chest Hospital
Esophageal Squamous Cell Carcinoma, Unresectable Locally Advanced Esophageal Cancer
Start: 2023-01-10
End: 2027-12-30
Target: 50
Updated: 2023-12-18
Phase 2
A Phase II Study for Nab-paclitaxel Plus Cisplatin vs Gemcitabine Plus Cispatin as First Line Chemotherapy in Advanced Biliary Tract Cancer
NCT04692051
Huazhong University of Science and Technology
Biliary Tract Cancer
Start: 2019-09-01
End: 2021-09-01
Target: 100
Updated: 2020-12-31
Related Papers
Nab-paclitaxel plus cisplatin versus gemcitabine plus cisplatin as first-line treatment in advanced biliary tract cancer: results of a multicentre, randomised, phase II trial.
2025-08-16
571. A PHASE I/II MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF INDUCTION IMMUNOCHEMOTHERAPY FOLLOWED BY CONCURRENT IMMUNO-CHEMORADIOTHERAPY IN UNRESECTABLE LA-ESCC
Diseases of the Esophagus
2024-09-01